Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma
Richard Hopkins,Wenwei Xiang,Damien Marlier,Veonice Bijin Au,Qianting Ching,Lynn Xue Wu,Rujun Guan,Bernett Lee,Whay-Kuang Chia,Who-Whong Wang,Joseph Wee,Joanna Ng,Rachael Cheong,Shuting Han,Axel Chu,Chit Lai Chee,Timothy Shuen,Michael Podinger,Alexander Lezhava,Han Chong Toh,John E. Connolly
DOI: https://doi.org/10.1016/j.ymthe.2020.09.040
IF: 12.91
2021-02-01
Molecular Therapy
Abstract:<p>Advanced, late stage Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) is incurable, and its treatment remains a clinical and therapeutic challenge. Results from a phase II clinical trial in advanced NPC patients employing a combined chemotherapy and EBV-specific T-Cell (EBVST) immunotherapy regimen, showed a response rate of 71.4%. Longitudinal analysis of patient samples showed that an increase in EBV DNA plasma concentrations, and the peripheral monocyte to lymphocyte ratio negatively correlated with overall survival. These parameters were combined into a multivariate analysis to stratify patients according to risk of death. Immunophenotyping at serial timepoints showed that low-risk individuals displayed significantly decreased amounts of monocytic myeloid-derived suppressor cells post-chemotherapy, which subsequently influenced successful CTL immunotherapy. Examination of the low-risk group two-weeks post EBVST infusion, showed that individuals with a greater overall survival possessed an increased frequency of CD8 central and effector memory T-cells, together with higher levels of plasma IFN-γ, and cytotoxic lymphocyte-associated transcripts. These results highlight the importance of rationally selecting chemotherapeutic agents and consideration of their impact on both systemic immune responses and downstream cellular immunotherapy outcomes.</p>
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology